Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens (AV-GBM-1) as an Adjunctive Therapy Following Primary Surgery Plus Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma

NCT03400917 is registered in ClinicalTrials.gov with Aivita Biomedical, Inc. as lead sponsor.

NCT NCT03400917
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03400917 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens (AV-GBM-1) as an Adjunctive Therapy Following Primary Surgery Plus Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma
Lead sponsor
Aivita Biomedical, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
June 20, 2018
Completion date
February 28, 2023
Enrollment
55 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

newly diagnosed glioblastoma